Ishita Drugs Exempt from Annual Secretarial Compliance Certificate

Ishita Drugs & Industries Ltd. has been exempted from filing the Annual Secretarial Compliance Certificate for the financial year ending March 31, 2026. The company confirmed its paid-up equity share capital stood at ₹2.99 crore and its Net Worth at ₹10.79 crore as of March 31, 2025. These figures are below the SEBI thresholds of ₹10 crore and ₹25 crore, respectively, which are required for this certification under SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Why This Exemption Matters

This exemption notably eases the compliance and administrative workload for Ishita Drugs. It allows management to focus more resources on core business operations instead of extensive regulatory filings. This provision is common for smaller listed companies, aligning regulatory demands with their operational scale.

Company Background

Ishita Drugs & Industries Ltd., part of the Ishita Group, has been manufacturing Active Pharma Ingredients (APIs), drug intermediates, and fine chemicals since its establishment in 1992. For the fiscal year 2025, the company reported revenues of ₹15.33 crore and a net profit of ₹0.87 crore. Its three-year average return on equity was 8.40%.

What Changes Now

The immediate impact is that Ishita Drugs is no longer required to prepare, file, or submit the Annual Secretarial Compliance Report for the 2025-26 financial year. This change simplifies its regulatory obligations. The company remains committed to fulfilling all other applicable SEBI and exchange regulations.

Market Context and Peers

Other smaller listed firms, such as Tirupati Finlease Ltd. and Sarthak Global Limited, have also received exemptions from the Annual Secretarial Compliance Report, meeting comparable paid-up capital and net worth criteria. This highlights a consistent regulatory approach for entities of similar size. In the API and drug intermediate manufacturing sector, Ishita Drugs' peers include Makers Laboratories Ltd., Everest Organics Ltd., and ANG Lifesciences India Ltd.

What to Watch Next

Investors will likely monitor the company's ongoing adherence to other SEBI and exchange regulations, its financial performance in upcoming quarters, and any future announcements regarding operational expansions or strategic initiatives.